Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enzolytics Inc (OP: ENZC )

0.0040 +0.0005 (+14.29%)
Streaming Delayed Price Updated: 10:26 AM EDT, May 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enzolytics Inc

< Previous 1 2 3 Next >
Enzolytics Reports Its Engagement of Scendea USA, Inc., a Leading International Product Development and Regulatory Consulting Group, To Guide the Progress Toward Clinical Trials and Market Approval for Its Itv-1 Anti-HIV Therapeutic
COLLEGE STATION, TX / ACCESSWIRE / December 29, 2021 / Enzolytics, Inc. has engaged Scendea USA, Inc. (www.scendea.com), a leading international product development and regulatory consulting group, to... 
From Enzolytics, Inc.
Via AccessWire
Exposures Product Safety
Enzolytics Announces Progress As It Recognizes World AIDS Day
COLLEGE STATION, TX / ACCESSWIRE / December 2, 2021 / Enzolytics wishes to recognize and acknowledge World AIDS Day - a day to call attention to the continued need for a more effective treatment for... 
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Intellectual Property Regulatory Compliance
Exposures Artificial Intelligence COVID-19 Intellectual Property
Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune", a Tested Immune Modulator based on U.S. Patent No. 8,309,072
COLLEGE STATION, TX / ACCESSWIRE / November 17, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced planned production and sale in the U.S. and North America of "Enzolytics... 
From Enzolytics, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Enzolytics, Inc. Announces Program for Creation of Multiple Monoclonal Antibodies for Veterinary Application Utilizing Hybridoma and Phage Display Technology
COLLEGE STATION, TX / ACCESSWIRE / November 8, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced a coherent protocol that it is executing to meet the Company's objective... 
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Exposures Artificial Intelligence COVID-19 Legal
Enzolytics Reports Its Progress Toward Completion Of Clinical Trials for Its ITV-1 ANTI-HIV Therapeutic and Securing Use Authorization Under the European Medicines Agency
COLLEGE STATION, TX / ACCESSWIRE / July 29, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has completed arrangements and agreements with Danhson (https://danhson.bg/en/) and Clinic... 
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Lead Legal
Enzolytics Announces the Appointment of Steve Sharabura as President of its Wholly Owned Subsidiary RobustoMed, Inc (A/K/A ENZO SUB)
COLLEGE STATION, TX / ACCESSWIRE / July 26, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) ("Enzolytics" and the "Company") announced today the appointment of Steve Sharabura as President of the Company's... 
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
COLLEGE STATION, TX / ACCESSWIRE / July 21, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) Enzolytics and Lonza Bioscience are combining their respective technologies to fast-track development and production... 
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Exposures Artificial Intelligence COVID-19 Legal
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc. for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
COLLEGE STATION, TX / ACCESSWIRE / July 20, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) ("Enzolytics" and the 'Company') announces the signing of a Letter of Intent (LOI) with Creative Biolabs ("Creative")... 
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Exposures Artificial Intelligence COVID-19 Legal
Enzolytics Announces Its Progress Toward Completion of Clinical Trials for Its Anti-HIV ITV-1 Therapeutic and Plans for Its Distribution Throughout Europe
COLLEGE STATION, TX / ACCESSWIRE / June 14, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has concluded definitive plans to advance its previously tested ITV-1 anti-HIV therapeutic... 
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Enzolytics Announces A Comprehensive Therapeutic Protocol For Production Of Monoclonal Antibodies To Address Ongoing And Future Pandemics
COLLEGE STATION, TX / ACCESSWIRE / June 7, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced a coherent protocol that it intends to execute to meet the Company's objective... 
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Intellectual Property Regulatory Compliance
Exposures Artificial Intelligence COVID-19 Intellectual Property
Enzolytics Announces the Discovery of Conserved, Immutable Target Sites on HTLV-1 and Plans To Commence Production of Monoclonal Antibodies Targeting These Sites
COLLEGE STATION, TX / ACCESSWIRE / May 26, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") today announced it has identified conserved, expectedly immutable sites on the HTLV-1 virus against... 
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Exposures Artificial Intelligence COVID-19 Legal
Enzolytics Inc. and Intel Corporation Co-Author White Paper on Use of Artificial Intelligence for Social Good
COLLEGE STATION, TX / ACCESSWIRE / May 17, 2021 /In a significant white paper, Enzolytics inc. (OTC PINK:ENZC) (http://enzolytics.com/) and Intel Corporation (https://www.intel.com) has published a... 
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Fraud Regulatory Compliance
Exposures Artificial Intelligence COVID-19 Legal
Enzolytics, Inc. Announces the Grant of a Distributorship License for the Right to Distribute its Anti-Hiv-1 Therapeeutic Itv-1 and a Stock Agreement Valued in Total At $7 Million US Dollars
COLLEGE STATION, TX / ACCESSWIRE / May 12, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has granted a distributorship license to a European pharma entity (the... 
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Enzolytics, Inc. Announces the Engaement of Ten Associates LLC As The Company's Strategic Communication Firm
COLLEGE STATION, TX / ACCESSWIRE / May 11, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has engaged TEN Associates LLC (the "Consultant") to assist the Company in... 
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Enzolytics Reports Progress On Its Multiple Therapeutics Platforms and Initiatives
COLLEGE STATION, TX / ACCESSWIRE / April 19, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company"). We continue to make great strides in the application of our multiple platforms for production... 
From Enzolytics, Inc.
Via AccessWire
Topics Artificial Intelligence Regulatory Compliance
Exposures Artificial Intelligence COVID-19 Legal
Enzolytics to Present At the Emerging Growth Conference on April 14, 2021
Enzolytics Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. COLLEGE STATION, TX... 
From Enzolytics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.